PhRMA lobbying spend increases 25% to $22 million for 2007

Share this article:

PhRMA spent more than $22 million lobbying the federal government last year, nearly a 25% increase from the amount spent in 2006, disclosure records filed by the group last week show.

According to the records, PhRMA spent $12 million in the secondhalf of 2007 lobbying against efforts including a bill to allow federal government negotiaton of prices directly with drug companies and legislation that would allow citizens to purchase lower-cost Rx meds from Canada and other countries. Congress did not pass either bill.

In 2007, PhRMA also lobbied against a patent reform bill, which remains under consideration in the Senate, and a prescription drug safety bill, which became law last September but did not include restrictions on DTC ads.

"This seems to be a case where the increase in lobbying activity is defensive, not offensive," Massie Ritsch of the Center for Responsive Politics, a government watchdog group, told the Associated Press.

PhRMA SVP Ken Johnson said in a published report that while the industry faced many challenges on Capitol Hill last year, most of the increased spending went toward advertisements urging Congress to reauthorize a program that provides healthcare to poor children.
"We would like to see every person in America have health insurance," Johnson said.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Channel

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...